BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
64.26
+0.81 (1.28%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions.

Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A.

The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally.

It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation.

The company was incorporated in 1996 and is headquartered in San Rafael, California.

BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical logo
Country United States
Founded 1996
IPO Date Jul 23, 1999
Industry Biotechnology
Sector Healthcare
Employees 3,401
CEO Alexander Hardy

Contact Details

Address:
770 Lindaro Street
San Rafael, California 94901
United States
Phone 415 506 6700
Website biomarin.com

Stock Details

Ticker Symbol BMRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001048477
CUSIP Number 09061G101
ISIN Number US09061G1013
Employer ID 68-0397820
SIC Code 2834

Key Executives

Name Position
Alexander Hardy President, Chief Executive Officer and Director
Dr. C. Greg Guyer Ph.D. Executive Vice President and Chief Technology Officer
Dr. Henry J. Fuchs M.D., Ph.D. Advisor
Erin Burkhart Group Vice President and Chief Accounting Officer
Dr. Kevin Eggan Ph.D. Chief Scientific Officer and Senior Vice President of Research and Early Development
Traci McCarty Group Vice President of Investor Relations
Humaira Serajuddin Senior Vice President and Chief Marketing Officer
Amy Wireman Executive Vice President and Chief People Officer
Dr. Ganesh Vedantham Ph.D. Senior Vice President of Technical Development
Marni Kottle Executive Vice President and Chief Corporate Affairs Officer

Latest SEC Filings

Date Type Title
Nov 12, 2024 144 Filing
Oct 31, 2024 10-Q Quarterly Report
Oct 29, 2024 8-K Current Report
Oct 3, 2024 UPLOAD Filing
Sep 30, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 24, 2024 8-K Current Report
Sep 4, 2024 8-K Current Report
Sep 2, 2024 UPLOAD Filing
Aug 28, 2024 8-K Current Report
Aug 22, 2024 8-K Current Report